Tirzepatide Weight Loss Causes Revealed: Reduced Appetite, Energy Intake and Fat Mass 2022EASD

Introduction: From September 19 to 23, 2022, the 2022 European Association for the Study of Diabetes Annual Conference, a major international conference in the field of endocrinology, was held
in Stockholm, Sweden in the form of "online + offline".
At the meeting, scholars shared a study
entitled "Tirzepatide can reduce appetite, energy intake and fat mass in patients with type 2 diabetes".

Dual receptor agonist Tirzepatide bisopatide

Tirzepatide (TZP), as a dual GIP and GLP-1 receptor agonist, is significantly superior to selective GLP-1RA
in glycemic control and weight loss.
Rodent models suggest that GIP-RA enhances GLP-1RA-induced food intake inhibition, reduces fat mass, and leads to weight loss
.

This randomized, double-blind, parallel-study compared changes in measures of baseline and 28 weeks of treatment, including energy intake (assessed by random lunches), appetite (visual analogue scale [VAS] rating hunger, satiety, expected food consumption [PFC], and satiety) in the TZP15 mgQW group (n=45), the semaglutide (SEMA) 1 mgQW (n=44), and placebo (PBO) (n=28)
。

Tirzepatide reduces fat mass and has a more significant weight loss effect

➤ Studies found that patients in the 15 mgTZP and 1 mg SEMA groups lost significantly less weight than baseline at 28 weeks, with a significant difference between groups (-4.
3 kg [95% CI -6.
8 to 1.
9]; p<0.
001).

➤ Fat mass in the 15 mg TZP group and 1 mg SEMA treatment group also decreased from baseline levels, 9.
7 kg and 5.
9 kg, respectively, with significant differences between groups (-3.
8 kg [95% CI -6.
2~-1.
4]; p=0.
002）
。

➤ Compared with baseline, energy intake was also significantly reduced in the 15 mg TZP treatment group and the 1 mg SEMA treatment group, -348.
4 kcal and -284.
1 kcal, respectively, with no statistically significant difference
between the groups.

➤TZP may reduce overall appetite and increase satiety by lowering PFC (mean p<0.
05
).
There was also no difference
in appetite ratings between the two groups.

conclusion

Therefore, it is believed that TZP may achieve a more significant weight loss effect than SEMA1mg (a selective GLP-1RA) by reducing fat mass
.
The total fasting appetite and energy intake of patients in the TZP group and the selective GLP-1RA group were significantly reduced and clinically significant
.
Since there was no significant difference in appetite and caloric intake between the two treatment groups, TZP may lead to this superior weight loss effect through other mechanisms
.
The mechanism of TZP weight loss remains to be eluted
by further research.

Translator's introduction

Deputy Chief Physician, Department of Endocrinology, Affiliated Hospital of Ningbo University School of Medicine

Graduated from Zhejiang University with a master's degree, he has been engaged in endocrinology for more than 10 years, and has studied in Shanghai Ruijin Hospital for half a year

At present, he is a youth committee member of the Endocrinology Branch of Ningbo Medical Association, and the teaching secretary of the Internal Medicine Base of the Affiliated Hospital of Ningbo University School of Medicine

He has presided over and participated in a number of provincial and municipal projects, published nearly 10 articles, and won awards
in many provincial and municipal competitions.